Summaries & Associations of Study Results
Levels from TR-397 C.I. Direct Blue 15
Target Organs and Levels of Evidence
NTP Technical Report Number 397
Produced from Chemtrack Database 05/19/05
CHEMICAL/ CAS NUMBER | PEER REVIEW DATE | PRIMARY USES | ROUTE/EXPOSURE LEVELS | STUDY LABORATORY |
---|---|---|---|---|
C.I. DIRECT BLUE 15 2429-74-5 |
11/19/90 | DYE FOR SILK, WOOL, VISCOSE, LEATHER, PAPER, CELLULOSE FIBERS. BIOLOGICAL STAIN. TINT FOR CINEMATOGRAPHIC FILMS. (TDB) | Dosed-Water RATS ONLY: 0,630,1250,2500 PPM (70,45,75,70 PER GROUP RESPECTIVELY) | Hazleton (Vienna) |
LEVELS OF EVIDENCE OF CARCINOGENICITY--ORGAN/TISSUE (NEOPLASM): | ||||
MR: CLEAR EVIDENCE | SKIN: BASAL CELL ADENOMA 2/50 8/35 23/65 26/50, BASAL CELL CARCINOMA 0/50 2/35 4/65 10/50, COMBINED 2/50 9/35 27/65 28/50; SEBACEOUS GLAND ADENOMA 0/50 1/35 7/65 3/50; SQUAMOUS CELL PAPILLOMA 2/50 3/35 5/65 8/50, SQUAMOUS CELL CARCINOMA 0/50 1/35 7/65 13/50, COMBINED 2/50 4/35 11/65 19/50 | |||
ZYMBAL GLAND: ADENOMA 0/50 2/35 2/65 4/50, CARCINOMA 1/50 3/35 8/65 17/50, COMBINED 1/50 5/35 10/65 20/50 | ||||
PREPUTIAL GLAND: ADENOMA 6/49 2/35 12/64 8/48, CARCINOMA 2/49 3/35 11/64 1/48, COMBINED 8/49 5/35 23/64 9/48 | ||||
LIVER: NEOPLASTIC NODULE 0/50 6/35 8/65 7/50, CARCINOMA 0/50 0/35 1/65 4/50, COMBINED 0/50 6/35 9/65 11/50 | ||||
ORAL CAVITY: SQUAMOUS CELL PAPILLOMA 0/50 9/35 18/65 15/50, SQUAMOUS CELL CARCINOMA 1/50 1/35 6/65 2/50, COMBINED 1/50 10/35 24/65 17/50 | ||||
INTESTINES: ADENOMATOUS POLYP 0/50 2/35 2/65 5/50, ADENOCARCINOMA 0/50 0/35 4/65 5/50, COMBINED 0/50 2/35 6/65 10/50 | ||||
MAY HAVE BEEN RELATED: | HEMATOPOIETIC SYSTEM: MONONUCLEAR CELL LEUKEMIA 17/50 19/35 28/65 20/50 | |||
BRAIN: ASTROCYTOMA 0/50 1/35 1/65 2/50 | ||||
NON-NEOPLASTIC LESIONS: | PREPUTIAL GLAND: ECTASIA | |||
LIVER: CYSTIC DEGENERATION; FOCAL CELLULAR ALTERATIONS; REGENERATION | ||||
SKIN: BASAL CELL HYPERPLASIA | ||||
ZYMBAL GLAND: ECTASIA; SQUAMOUS HYPERPLASIA | ||||
FR: CLEAR EVIDENCE | SKIN: SQUAMOUS CELL PAPILLOMA 0/50 2/35 5/65 5/50, SQUAMOUS CELL CARCINOMA 0/50 0/35 1/65 0/50, COMBINED 0/50 2/35 6/65 5/50 | |||
ZYMBAL GLAND: ADENOMA 0/50 1/35 5/65 3/50, CARCINOMA 0/50 4/35 7/65 14/50, COMBINED 0/50 4/35 11/65 17/50 | ||||
CLITORAL GLAND: ADENOMA 5/50 5/31 12/64 12/50, CARCINOMA 2/50 6/31 12/64 15/50, COMBINED 7/50 11/31 24/64 27/50 | ||||
LIVER: NEOPLASTIC NODULE 0/50 0/35 2/65 4/50, CARCINOMA 0/50 0/35 0/65 1/50, COMBINED 0/50 0/35 2/65 5/50 | ||||
ORAL CAVITY: SQUAMOUS CELL PAPILLOMA 2/50 3/35 12/65 9/50, SQUAMOUS CELL CARCINOMA 0/50 1/35 8/65 6/50, COMBINED 2/50 4/35 19/65 15/50 | ||||
INTESTINES: ADENOMATOUS POLYP 0/50 0/35 3/65 1/50; ADENOCARCINOMA 0/50 0/35 1/65 3/50 | ||||
UTERUS/CERVIX: ADENOMA 0/50 0/35 1/65 1/50, ADENOCARCINOMA 1/50 0/35 0/65 3/50, COMBINED 1/50 0/35 1/65 4/50 | ||||
HEMATOPOIETIC SYSTEM: MONONUCLEAR CELL LEUKEMIA 7/50 13/35 27/65 15/50 | ||||
NON-NEOPLASTIC LESIONS: | CLITORAL GLAND: SQUAMOUS HYPERPLASIA | |||
LIVER: FOCAL CELLULAR ALTERATIONS; REGENERATION | ||||
ZYMBAL GLAND: ECTASIA; HYPERPLASIA |
Web page last updated on October 25, 2007